Works matching IS 01676997 AND DT 2017 AND VI 35 AND IP 3

Results: 16

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 290, doi. 10.1007/s10637-016-0418-8

By:

Kyriakopoulos, Christos;
Braden, Amy;
Kolesar, Jill;
Eickhoff, Jens;
Bailey, Howard;
Heideman, Jennifer;
Liu, Glenn;
Wisinski, Kari

Publication type:

Article

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 315, doi. 10.1007/s10637-016-0419-7

By:

Shapiro, Geoffrey;
Vaishampayan, Ulka;
LoRusso, Patricia;
Barton, Jeremy;
Hua, Steven;
Reich, Steven;
Shazer, Ronald;
Taylor, Carrie;
Xuan, Dawei;
Borghaei, Hossein

Publication type:

Article

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 298, doi. 10.1007/s10637-016-0420-1

By:

Forero, Andres;
Bendell, Johanna;
Kumar, Prasanna;
Janisch, Linda;
Rosen, Michael;
Wang, Qiang;
Copigneaux, Catherine;
Desai, Madhuri;
Senaldi, Giorgio;
Maitland, Michael

Publication type:

Article

A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 307, doi. 10.1007/s10637-016-0422-z

By:

Mukai, Hirofumi;
Kogawa, Takahiro;
Matsubara, Nobuaki;
Naito, Yoichi;
Sasaki, Masaoki;
Hosono, Ako

Publication type:

Article

Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 251, doi. 10.1007/s10637-016-0424-x

By:

Jiang, Juhong;
Lu, Yuanzhi;
Li, Zhi;
Li, Liping;
Niu, Daoli;
Xu, Wenwei;
Liu, Jing;
Fu, Lin;
Zhou, Ziqing;
Gu, Yingying;
Xia, Fen

Publication type:

Article

Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 386, doi. 10.1007/s10637-017-0425-4

By:

Fountzilas, Christos;
Stuart, Selena;
Hernandez, Brian;
Bowhay-Carnes, Elizabeth;
Michalek, Joel;
Sarantopoulos, John;
Karnad, Anand;
Patel, Sukeshi;
Weitman, Steven;
Mahalingam, Devalingam

Publication type:

Article

State-dependent block of voltage-gated sodium channels by the casein-kinase 1 inhibitor IC261.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 277, doi. 10.1007/s10637-017-0429-0

By:

Föhr, Karl;
Knippschild, Uwe;
Herkommer, Anna;
Fauler, Michael;
Peifer, Christian;
Georgieff, Michael;
Adolph, Oliver

Publication type:

Article

Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 269, doi. 10.1007/s10637-017-0430-7

By:

Takahara, Naminatsu;
Isayama, Hiroyuki;
Nakai, Yousuke;
Sasaki, Takashi;
Ishigaki, Kazunaga;
Saito, Kei;
Akiyama, Dai;
Uchino, Rie;
Mizuno, Suguru;
Yagioka, Hiroshi;
Kogure, Hirofumi;
Togawa, Osamu;
Matsubara, Saburo;
Ito, Yukiko;
Toda, Nobuo;
Tada, Minoru;
Koike, Kazuhiko

Publication type:

Article

A truncated apoptin protein variant selectively kills cancer cells.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 260, doi. 10.1007/s10637-017-0431-6

By:

Ruiz-Martínez, Santiago;
Castro, Jessica;
Vilanova, Maria;
Bruix, Marta;
Laurents, Douglas;
Ribó, Marc;
Benito, Antoni

Publication type:

Article

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 392, doi. 10.1007/s10637-017-0434-3

By:

Sasada, Shinsuke;
Ushirozawa, Nobuko;
Kobayashi, Noriko;
Fujiwara, Yutaka;
Tamura, Kenji;
Yamamoto, Noboru

Publication type:

Article

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 324, doi. 10.1007/s10637-017-0438-z

By:

Fu, S.;
Hirte, H.;
Welch, S.;
Ilenchuk, T.;
Lutes, T.;
Rice, C.;
Fields, N.;
Nemet, A.;
Dugourd, D.;
Piha-Paul, S.;
Subbiah, V.;
Liu, L.;
Gong, J.;
Hong, D.;
Stewart, J.

Publication type:

Article

Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 375, doi. 10.1007/s10637-017-0443-2

By:

Piska, Kamil;
Koczurkiewicz, Paulina;
Bucki, Adam;
Wójcik-Pszczoła, Katarzyna;
Kołaczkowski, Marcin;
Pękala, Elżbieta

Publication type:

Article

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 334, doi. 10.1007/s10637-017-0446-z

By:

Salgia, Ravi;
Weaver, R.;
McCleod, Michael;
Stille, John;
Yan, S.;
Roberson, Stephanie;
Polzer, John;
Flynt, Amy;
Raddad, Eyas;
Peek, Victoria;
Wijayawardana, Sameera;
Um, Suzane;
Gross, Steve;
Connelly, Mark;
Morano, Carrie;
Repollet, Madeline;
Sanders, Renouard;
Baeten, Kurt;
D'Haese, David;
Spigel, David

Publication type:

Article

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 345, doi. 10.1007/s10637-017-0450-3

By:

Thomas, M.;
Sadjadian, P.;
Kollmeier, J.;
Lowe, J.;
Mattson, P.;
Trout, J.;
Gargano, M.;
Patchen, M.;
Walsh, R.;
Beliveau, M.;
Marier, J.;
Bose, N.;
Gorden, K.;
Schneller, F.

Publication type:

Article

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Published in:

2017

By:

Fu, S.;
Hirte, H.;
Welch, S.;
Ilenchuk, T.;
Lutes, T.;
Rice, C.;
Fields, N.;
Nemet, A.;
Dugourd, D.;
Piha-Paul, S.;
Subbiah, V.;
Liu, L.;
Gong, J.;
Hong, D.;
Stewart, J.

Publication type:

Erratum

Current achievements and future perspectives of metronomic chemotherapy.

Published in:

Investigational New Drugs, 2017, v. 35, n. 3, p. 359, doi. 10.1007/s10637-016-0408-x

By:

Romiti, Adriana;
Falcone, Rosa;
Roberto, Michela;
Marchetti, Paolo

Publication type:

Article